Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aflibercept and VEGF levels in Retinal Vein Occlusion
NCT04707625Phase 4Terminated
- Sponsor
- Wake Forest University Health Sciences
- Start
- Oct 2021
- Primary completion
- Dec 2023
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 4 trial of aflibercept in retinal vein occlusion (RVO), sponsored by Wake Forest University Health Sciences. Started Oct 2021; status: terminated.
02
Drugs
aflibercept
03
Conditions
retinal vein occlusion (RVO)
Beyond the preview
Go deeper on NCT04707625.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04707625.